ABSTRACT. Four types of commercially available feline calicivirus (FCV) vaccine were compared in terms of their efficacy on the basis of the ability of the sera of specific-pathogen-free cats immunized by two injections of each type of vaccine to neutralize FCV field isolates. Each vaccine immune serum neutralized relatively well strains F4, F9, and 255, which were FCV laboratory strains. As to 36 strains of field isolates, however, vaccines A, B, C, and D immune sera did not neutralize 18-20 of the strains (50.0%-55.6%), 19-22 of the strains (52.8%-61.1%), 22-25 of the strains (61.1%-69.4%), and 8-16 of the strains (22.2%-44.4%), respectively. These results indicate that there is much difference in neutralizing antigenicity between the existing vaccine strains and the FCV strains that are prevalent in Japan, suggesting the need for improvement of FCV vaccines.-KEY WORDS: feline calicivirus, neutralizing antigenicity, vaccine immune serum.
The FCV used were laboratory strains F4, F9, and 255 and 36 strains of field isolates prepared in Japan in 1991 [9] . Of these 36 strains of field isolates, 23 isolates, 7 isolates, 2 isolates, and each of the remaining 4 isolates were obtained from the oral or nasal swabs of the cats suspected of having viral respiratory diseases, which had been maintained in Tokyo, and Tottori, Yamagata, Ehime, Okayama, Kanagawa, and Saitama Prefectures, respectively. All of the field isolates were purified by three rounds of plaque cloning and propagated in Crandell feline kidney (CrFK) cells.
The immune sera were prepared from eight 12-monthold SPF cats immunized by two injections, with an interval of 3 weeks, of each type of feline triple combined vaccine. Serum samples collected 3 weeks after the second injection were used as the immune sera.
Serial two-fold dilutions of the test sera were mixed with an equal volume of an FCV strain suspension containing approximately 200 TCID 50 and the mixtures were incubated at 37°C for 60 min. Each mixture was then inoculated into the CrFK cell cultures in flat-bottomed microplates, and incubated in an atmosphere of 5% CO 2 in air at 37°C for 4 days. Each serum dilution was plated in duplicate. The antibody titer was expressed as the reciprocal of the highest dilution of serum that completely inhibited a viral cytopathic effect. Table 1 shows the neutralizing antibody titers of FCV vaccine immune sera against three FCV laboratory strains and 36 strains of FCV field isolates. Each immune serum neutralized three laboratory strains well, with the exception of the reactivity of the vaccine C immune serum against strain 255. The F9 strain particularly was neutralized well with every immune serum. Against the 36 field isolates, however, the immune sera showed various neutralizing antibody titers, and there were eight isolates (91-4, 91-16, 91-19, 91-28, 91-29, 91-34, 91-36, and 91-38) which were not neutralized by any immune serum. Table 2 shows the Feline calicivirus (FCV) is an important cause of acute oral and respiratory disease in cats [4] . Many strains of FCV have been isolated in the world and the serological relationships among these isolates have been analyzed by using polyclonal antibodies [2, 3, 6, 8] . Monoclonal antibody analysis has also been applied to FCV isolates, and has shown both antigenic variation and the presence of at least seven neutralizing epitopes [11, 12] . Early studies using conventional cross-neutralization tests showed some differences between isolates, but the isolates are reasonably closely related and constitute one serotype [8] . According to the results of these studies, a vaccine using the F9 strain, a highly cross-reactive FCV strain, as a prototype was developed, and has been widely used to date. In the 1990s, however, some studies have shown that the rate of FCV isolation from oropharyngeal swabs of cats with upper respiratory disease is higher than that of feline herpes virus (FHV) [1, 5] . It has also been reported that some FCV isolates, which are more resistant to FCV-F9 antibody, are increasing, suggesting the need for re-examination of the efficacy of the existing vaccines [1, 6, 7] . The most desirable method of evaluating the efficacy of the commercially available vaccines for FCV isolates is to challenge the cats immunized by injection of the vaccines to each isolate. However, it is difficult to employ this method in many field isolates. In this study, the efficacy of the existing FCV vaccines was investigated on the basis of reactivity in the neutralization test using the sera of specificpathogen-free (SPF) cats immunized by two injections of commercially available FCV vaccines and 36 strains of field isolates in Japan.
The FCV vaccines used were four types of commercially available feline triple (FCV, FHV, and feline parvovirus) combined vaccine. Of these vaccines, the vaccines A and B are attenuated live vaccines, and the vaccines C and D are inactivated. Also, the vaccine D is a multivalent vaccine including two types of FCV strain. distribution of neutralizing antibody titers of these immune sera against 39 strains of FCV including the laboratory strains. The #20 and #C3 vaccine A immune sera did not neutralize 20 strains (55.6%) and 18 strains (50.0%) of FCV, respectively. Similarly, the #C1 and #C4 vaccine B immune sera did not neutralize 19 strains (52.8%) and 22 strains (61.1%), #C2 and #C5 vaccine C immune sera, 26 strains (66.6%) and 23 strains (60.0%), and #C6 and #A7 vaccine D immune sera, eight strains (22.2%) and 16 strains (44.4%), respectively, of FCV.
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